Home » Stocks » Forma Therapeutics

Forma Therapeutics Holdings, Inc. (FMTX)

Stock Price: $43.54 USD -0.80 (-1.80%)
Updated Jul 10, 2020 4:00 PM EDT - Market closed
After-hours: $43.56 +0.02 (0.05%) Jul 10, 4:11 PM

Stock Price Chart

Key Info

Market Cap 1.81B
Revenue (ttm) 28.55M
Net Income (ttm) n/a
Shares Out 38.58M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 10, 2020
Last Price $43.54
Previous Close $44.34
Change ($) -0.80
Change (%) -1.80%
Day's Open 44.35
Day's Range 43.13 - 46.74
Day's Volume 571,202
52-Week Range 37.50 - 50.00

More Stats

Market Cap 1.81B
Enterprise Value 1.66B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 38.58M
Float n/a
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 162,102
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 63.31
PB Ratio 11.82
Revenue 28.55M
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 142.44M
Net Cash / Share 3.43
Gross Margin -37.68%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-38.72%-
Gross Profit101164
Operating Income-40.459.69
Net Income-34.795.29
Shares Outstanding10.9010.90
Earnings Per Share-4.93-0.04
Operating Cash Flow-34.49-133
Capital Expenditures-0.53-3.39
Free Cash Flow-35.02-136
Cash & Equivalents173152
Net Cash / Debt173152
Book Value18.25-48.87
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Forma Therapeutics Holdings, Inc.
Country United States
Employees 77
CEO Frank D. Lee

Stock Information

Ticker Symbol FMTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: FMTX
IPO Date June 19, 2020


Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing FT-2102, an oral selective small molecule investigational agent that is designed to bind to and inhibit mutated IDH1 enzymes, which is being evaluated in a Phase 2 trial for relapsed/refractory AML, as well as an exploratory Phase 1 trial for glioma; and FT-4101 and FT-8225, which are selective fatty acid synthase inhibitors. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.